2,116 results on '"Viardot A"'
Search Results
2. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
3. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
4. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
5. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
6. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies
7. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
8. Nodales Marginalzonenymphom
9. Dehydroepiandrosterone supplementation and the impact of follicular fluid metabolome and cytokinome profiles in poor ovarian responders
10. Connecting the Dots of Care: A pilot study linking Aboriginal and/or Torres Strait Islander peoples with diabetes care in hospital, using hospital pharmacists
11. Connecting the Dots of Care: A pilot study linking Aboriginal and/or Torres Strait Islander peoples with diabetes care in hospital, using hospital pharmacists
12. Post-pandemic implications for crisis innovation: A technological innovation view
13. Standardization for platform ecosystems
14. Outcomes and cost analysis of single-embryo transfer versus double-embryo transfer
15. Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated
16. S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
17. P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13
18. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies
19. Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
20. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
21. Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
22. Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model
23. #29 : A Retrospective Review of Patients Undergoing Fertility Preservation in a Tertiary Institution in Singapore Over 10 Years
24. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
25. Naissance de la bibliophilie : les cabinets de livres rares
26. Innovation and climate change: A review and introduction to the special issue
27. General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
28. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
29. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years
30. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
31. Le dernier sorcier : a chamber opera in two acts = The last sorcerer
32. Nodal Marginal Zone Lymphoma
33. First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
34. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
35. Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab
36. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
37. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
38. Implications of the coronavirus (COVID-19) outbreak for innovation: Which technologies will improve our lives?
39. Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study
40. Internal and external financing of innovation : Sectoral differences in a longitudinal study of European firms
41. T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
42. The impact of the 2008 financial crisis on innovation: A dominant design perspective
43. Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model
44. Roux-en-Y gastric bypass and gastric sleeve surgery result in long term bone loss
45. Saint-Saëns, the Playful
46. Enhancing the accuracy of polycystic ovary syndrome diagnosis
47. #29 : A Retrospective Review of Patients Undergoing Fertility Preservation in a Tertiary Institution in Singapore Over 10 Years
48. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
49. SGLT2 Inhibitor–Induced Ketoacidosis in a Patient Without Diabetes
50. Perspektiven der CAR-T-Zell-Therapie
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.